x
Filter:
Filters applied
- Reviews
- Peyrin-Biroulet, LaurentRemove Peyrin-Biroulet, Laurent filter
Publication Date
Please choose a date range between 2012 and 2021.
Author
- Danese, Silvio3
- Bonovas, Stefanos2
- D'Amico, Ferdinando2
- Pouillon, Lieven2
- Achit, Hamza1
- Argollo, Marjorie1
- Ayav, Carole1
- Bommelaer, Gilles1
- Buisson, Anthony1
- Chevaux, Jean-Baptiste1
- Elquza, Emad1
- Fazio, Maria1
- Fiorino, Gionata1
- Frimat, Luc1
- Gilardi, Daniela1
- Gower-Rousseau, Corinne1
- Guillemin, Francis1
- Guillo, Lucas1
- Hart, Ailsa1
- Leone, Salvo1
- Magro, Fernando1
- Olivera, Pablo1
- Radice, Simona1
- Taleban, Sasha1
Reviews
5 Results
- Review Article
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know
Digestive and Liver DiseaseVol. 53Issue 6p691–696Published online: February 6, 2021- Lucas Guillo
- Ferdinando D'Amico
- Hamza Achit
- Carole Ayav
- Francis Guillemin
- Silvio Danese
- and others
Cited in Scopus: 5The kidney function monitoring is recommended in routine practice to detect 5-aminosalicylic acid (5-ASA) related nephrotoxicity, although is not standardized. The optimal monitoring is unknown, especially the best timing and which tests to perform. We summarized why, how, and when to perform the monitoring for patients treated with 5-ASA and provided an overview of the current guidelines on this topic. - Review Article
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group
Digestive and Liver DiseaseVol. 52Issue 2p138–142Published online: December 4, 2019- Ferdinando D’Amico
- Lieven Pouillon
- Marjorie Argollo
- Ailsa Hart
- Gionata Fiorino
- Elena Vegni
- and others
Cited in Scopus: 20The high cost of biological drugs for patients with inflammatory bowel disease (IBD) considerably impacts on health-care budgets. Since the patent of biological products expired, cheaper biosimilars have entered the market. Available data coming from real-world cohorts and clinical trials indicate that the efficacy and safety of biosimilars is comparable to that of the originator drugs. Treating IBD patients with a biosimilar may be complicated by the risk of the nocebo effect, a negative effect of a pharmacological or non-pharmacological treatment, induced by patients’s expectations and unrelated to the physiological action of the treatment. - Review Article
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence
Digestive and Liver DiseaseVol. 51Issue 3p327–334Published online: November 16, 2018- Pablo Olivera
- Silvio Danese
- Lieven Pouillon
- Stefanos Bonovas
- Laurent Peyrin-Biroulet
Cited in Scopus: 16Biologics against tumor necrosis factor (anti-TNF) have dramatically changed the management of moderate-to-severe ulcerative colitis (UC). In pivotal clinical trials, golimumab showed efficacy as induction and maintenance therapy in anti-TNF naïve UC patients. However, confirmatory data on effectiveness in the real world setting are needed. - Review Article
Cancer and inflammatory bowel disease in the elderly
Digestive and Liver DiseaseVol. 48Issue 10p1105–1111Published online: June 9, 2016- Sasha Taleban
- Emad Elquza
- Corinne Gower-Rousseau
- Laurent Peyrin-Biroulet
Cited in Scopus: 21Cancer may be a complication of inflammatory bowel disease (IBD) or its treatments. In older Crohn's disease and ulcerative colitis patients, the risk of malignancy is of particular concern. IBD diagnosis at an advanced age is associated with earlier development of colitis-associated colorectal cancer. Thiopurine use in older IBD patients is tied to an increased risk of non-Hodgkin's lymphoma, nonmelanoma skin cancer, and urinary tract cancers. Additionally, older age is accompanied by multimorbidity, an increased risk of malnutrition, and decreased life expectancy, factors that complicate the management of cancer in the elderly. - Review Article
Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence
Digestive and Liver DiseaseVol. 44Issue 6p453–460Published online: January 20, 2012- Anthony Buisson
- Jean-Baptiste Chevaux
- Gilles Bommelaer
- Laurent Peyrin-Biroulet
Cited in Scopus: 53Ileocolonoscopy remains the gold standard in diagnosing postoperative recurrence. After excluding stricture, wireless capsule endoscopy seemed accurate in small series, but no validated score is available. Ultrasonography is a non-invasive diagnostic method reducing radiation exposure and emerging as an alternative tool for identifying post-operative recurrence. Computed tomography enteroclysis yields objective morphologic criteria that help differentiate between recurrent disease and fibrostenosis at the anastomotic site, but ionising radiation exposure limits its use.